AgomAb Therapeutics NV (NASDAQ:AGMB) Given Average Recommendation of “Moderate Buy” by Analysts

AgomAb Therapeutics NV (NASDAQ:AGMB) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $33.00.

AGMB has been the subject of a number of recent analyst reports. B. Riley Financial assumed coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price for the company. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $35.00 price objective on the stock.

AgomAb Therapeutics Trading Up 3.4%

NASDAQ AGMB opened at $15.00 on Tuesday. AgomAb Therapeutics has a 1 year low of $8.75 and a 1 year high of $17.82. The business has a 50-day simple moving average of $12.31.

AgomAb Therapeutics (NASDAQ:AGMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. As a group, analysts anticipate that AgomAb Therapeutics will post -1.84 EPS for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.